Change Language:

Esophageal adenocarcinoma is a malignant neoplasm arising from glandular epithelium and is currently the most common histological type of esophageal cancer in Western countries. Its development is closely associated with metaplastic transformation of the distal esophageal mucosa, typically in response to chronic exposure to acidic and biliary gastric contents. Anatomically, adenocarcinoma develops almost exclusively in the distal third of the esophagus and at the gastroesophageal junction, and differs from squamous cell carcinoma in both pathogenetic mechanisms and epidemiological distribution. Its biological behavior is characterized by progressive infiltrative growth, with early involvement of the deeper esophageal wall and regional lymph nodes, favored by the rich submucosal lymphatic network and anatomical continuity with gastric lymph-node stations.

The natural history of esophageal adenocarcinoma typically follows a well-defined sequence progressing from normal esophageal mucosa to intestinal metaplasia, known as Barrett esophagus, then to low- and high-grade dysplasia, and finally to invasive carcinoma. This multistep pathway develops in the setting of chronic inflammatory injury sustained by gastroesophageal reflux, with progressive accumulation of genetic and epigenetic alterations involving the control of cell proliferation, apoptosis, and genomic stability. In the early stages, the disease may remain clinically silent or present with nonspecific symptoms, whereas increasing tumor mass leads to progressive dysphagia, weight loss, and signs of esophageal obstruction. As with other esophageal neoplasms, diagnosis is frequently made at an advanced stage, with important prognostic implications.

Diagnostic evaluation and staging of esophageal adenocarcinoma require an integrated approach combining upper gastrointestinal endoscopy with targeted biopsies, endoscopic ultrasound to define the depth of mural infiltration and locoregional lymph-node involvement, and cross-sectional imaging to assess distant spread. In selected cases, metabolic characterization by PET can identify occult disease sites and refine the therapeutic strategy. Treatment is generally multimodal and is planned within dedicated multidisciplinary teams, with the aim of maximizing oncological control while preserving digestive function and quality of life as far as possible. Despite progress over recent decades, advanced esophageal adenocarcinoma remains associated with an overall poor prognosis, making prevention and early-detection strategies central in at-risk populations.

The epidemiology of esophageal adenocarcinoma has changed profoundly over recent decades, particularly in high-income countries. A marked rise in incidence has been observed in North America, Western Europe, and Australia, making this histological type more common than squamous cell carcinoma. This change reflects a true epidemiological transition closely linked to the spread of predisposing conditions such as chronic gastroesophageal reflux, obesity, and lifestyle changes. Globally, however, adenocarcinoma still accounts for a minority of esophageal cancers, with a highly variable relative burden across geographical regions.

In Western countries, the increase in incidence has been especially evident since the late twentieth century and has predominantly affected men. At the same time, many of these regions have seen a decline in squamous cell carcinoma related to reduced tobacco and alcohol consumption, whereas adenocarcinoma has followed the opposite trend. In Asia and Africa, by contrast, esophageal adenocarcinoma remains relatively uncommon, with some exceptions in urbanized areas where risk patterns similar to those in Western countries are emerging. This uneven geographical distribution underscores the decisive role of environmental and behavioral factors in disease development.

Demographically, esophageal adenocarcinoma shows a marked male predominance, with male-to-female ratios often exceeding 5:1 in Western series. Diagnosis occurs mainly in the sixth and seventh decades of life, although cases in younger individuals are not uncommon when multiple risk factors have been present for a prolonged period. Significant ethnic differences have also been described, with a higher risk among Caucasian individuals than among other groups, even with comparable exposure to the main environmental determinants.

The principal risk factor for esophageal adenocarcinoma is chronic gastroesophageal reflux. Repeated exposure of the distal esophageal mucosa to acid and bile salts causes persistent inflammatory injury that promotes the development of intestinal metaplasia. Barrett esophagus is the most important recognized precursor condition, with the risk of progression to carcinoma increasing in the presence of dysplasia, particularly high-grade dysplasia. The duration and severity of reflux symptoms, as well as the length of the metaplastic segment, significantly influence individual risk.

Obesity, particularly visceral obesity, is an important independent determinant. Increased intra-abdominal pressure promotes acid reflux, while adipose tissue acts as an active endocrine organ, producing proinflammatory cytokines and adipokines that may contribute to a microenvironment favorable to carcinogenesis. The risk associated with obesity has also been demonstrated in individuals without evident reflux symptoms, suggesting additional pathogenetic mechanisms beyond direct chemical injury alone.

Other behavioral factors include cigarette smoking, which increases the risk of esophageal adenocarcinoma, although to a lesser extent than for squamous cell carcinoma. Tobacco acts synergistically with reflux by enhancing mucosal injury and interfering with tissue-repair processes. The association with alcohol consumption is less pronounced and is not a central determinant for this histological type. Some studies have also suggested that high-calorie diets low in fiber, fruit, and vegetables may modify risk through inflammatory and metabolic mechanisms.

Conditions such as hiatal hernia are frequently associated with esophageal adenocarcinoma because they facilitate chronic reflux and increase its severity. Conversely, Helicobacter pylori infection, although a risk factor for other gastric malignancies, appears to have a protective effect against esophageal adenocarcinoma in some populations, probably through reduced gastric acid secretion; this issue remains debated and does not alter clinical indications for eradication when appropriate.

Overall, esophageal adenocarcinoma results from the interaction of chronic reflux, individual susceptibility, and lifestyle-related factors. The rapid growth in incidence in Western countries makes primary prevention measures aimed at weight control, reflux management, and reduction of modifiable exposures a priority, together with early identification of individuals with Barrett esophagus.

For esophageal adenocarcinoma, population-based screening programs do not exist, as is the case for other malignancies with a low incidence in the general population. The lack of sufficiently accurate noninvasive tests and the unfavorable cost-effectiveness of widespread endoscopic screening make this strategy impractical on a large scale. Early diagnosis is therefore pursued through selective approaches targeting groups with a substantially increased risk.

The main setting for selective screening is patients with Barrett esophagus. In these individuals, periodic endoscopic surveillance is an established practice aimed at detecting dysplasia or early-stage carcinoma. Endoscopy with systematic biopsies according to standardized protocols allows the evolution of metaplastic mucosa to be monitored and lesions with the greatest potential for progression to be identified promptly.

The frequency of endoscopic surveillance in patients with Barrett esophagus is tailored to the degree of histological abnormality. In the absence of dysplasia, examinations are generally spaced over time, whereas dysplasia, especially high-grade dysplasia, requires closer monitoring and integration of endoscopic treatment strategies. This approach allows neoplasia to be detected at an early stage, when it may be curable with techniques less invasive than conventional surgery.

In individuals with chronic gastroesophageal reflux and multiple risk factors, such as male sex, older age, and obesity, diagnostic endoscopy may be considered to identify Barrett esophagus. This assessment does not constitute universal screening, but rather a targeted risk-stratification strategy designed to select patients who may benefit from a structured surveillance program.

Advanced endoscopic techniques, including chromoendoscopy and optical imaging methods, have improved the ability to detect areas of dysplasia or superficial carcinoma within metaplastic mucosa. These tools increase diagnostic sensitivity and reduce the risk of inadequate sampling, particularly in longer or irregular Barrett segments. Their use, however, requires specific expertise and is generally concentrated in highly experienced centers.

In recent years, innovative minimally invasive screening strategies based on esophageal cell sampling and molecular biomarker analysis have also been explored. These approaches aim to identify metaplasia or dysplasia early without systematically resorting to endoscopy, but they have not yet acquired a defined role in routine clinical practice.

In summary, screening for esophageal adenocarcinoma is not indicated in the general population, whereas targeted surveillance of patients with Barrett esophagus and other high-risk subgroups is a rational and effective strategy. Incorporating endoscopic monitoring programs into structured clinical pathways can bring diagnosis forward and improve clinical outcomes while reducing exposure to unnecessary procedures.

The biology of esophageal adenocarcinoma typically develops in the setting of an acquired metaplastic transformation of the distal esophageal epithelium in response to chronic, persistent injury caused by gastroesophageal reflux. The normal stratified squamous epithelium of the esophagus, which is not designed to tolerate prolonged exposure to hydrochloric acid, bile salts, and duodenal contents, undergoes an adaptive process leading to its replacement by intestinal-type columnar epithelium known as Barrett esophagus. This condition is the principal biological precursor of esophageal adenocarcinoma and represents a paradigmatic example of carcinogenesis driven by chronic inflammation.

Within Barrett mucosa, the metaplastic epithelium contains mucus-secreting glands and goblet cells, with an intestinal differentiation program supported by transcription factors such as CDX2. Persistence of the injurious stimulus creates an environment characterized by chronic inflammation, oxidative stress, and repeated cycles of injury and regeneration, which promote the progressive accumulation of molecular alterations. A histopathological continuum is thereby established, encompassing nondysplastic intestinal metaplasia, low-grade dysplasia, high-grade dysplasia, and invasive carcinoma. Progression along this axis is neither linear nor inevitable, but reflects the dynamic interaction between genetic susceptibility, the intensity of environmental injury, and tissue-response capacity.

A crucial event in the transition to invasiveness is loss of basement-membrane integrity, which allows neoplastic cells to extend into the lamina propria and submucosa. At this stage, glandular architecture becomes irregular, with complex dysplastic structures, gland fusion, and infiltrative growth. The rich submucosal lymphatic network of the distal esophagus favors early lymph-node spread, explaining the frequent discrepancy between apparently limited macroscopic size and advanced stage. Depth of mural invasion and vascular and lymphatic involvement are direct indicators of biological aggressiveness.

At the genetic level, esophageal adenocarcinoma is characterized by marked chromosomal instability, with frequent amplifications, deletions, and structural rearrangements. TP53 alterations are among the earliest and most recurrent events and may already be detected at the dysplasia stage, reflecting loss of DNA-damage control and cell-cycle arrest. Unlike squamous cell carcinoma, adenocarcinoma often shows alterations in genes involved in regulating glandular growth and receptor signaling, with amplification of ERBB2 (HER2), EGFR, MET, FGFR2 and dysregulation of KRAS in a proportion of cases. CDKN2A alterations, with loss of p16, contribute to dysregulation of the G1/S checkpoint.

Major signaling pathways are profoundly altered, including PI3K/AKT/mTOR, MAPK, WNT/β-catenin, TGFβ, and pathways associated with the endoplasmic-reticulum stress response. Data from large genomic cohorts, including TCGA studies, have demonstrated substantial molecular heterogeneity, with subgroups characterized by marked chromosomal instability, DNA-repair defects, or mutational profiles associated with chronic acid and bile exposure. This molecular complexity is reflected in considerable variability in clinical behavior.

Alongside genetic alterations, epigenetic changes play a central role in carcinogenesis. Hypermethylation of tumor-suppressor gene promoters, post-translational histone modifications, and microRNA dysregulation contribute to stabilization of the neoplastic phenotype. MicroRNAs such as miR-21 and miR-192 are frequently overexpressed and promote proliferation and resistance to apoptosis, whereas microRNAs associated with maintenance of differentiated epithelium are reduced. These epigenetic alterations amplify the effects of genetic mutations and favor clonal expansion of selected cell populations.

The tumor microenvironment is a major determinant of esophageal adenocarcinoma progression. Chronic reflux-induced inflammation produces infiltration by innate and adaptive immune cells, with release of mediators such as IL-6, IL-8, TNF, and TGFβ, which promote proliferation, epithelial–mesenchymal transition, and invasiveness. Cancer-associated fibroblasts contribute to extracellular-matrix remodeling and create an environment permissive to growth. Intratumoral hypoxia induces HIF-1α, promoting VEGF-mediated angiogenesis and metabolic adaptations that sustain survival under conditions of limited nutrient supply.

At the immunological level, esophageal adenocarcinoma has a heterogeneous microenvironment with variable lymphocytic infiltration. PD-L1 expression on both tumor cells and infiltrating immune cells reflects active immune-evasion mechanisms. Some subgroups, particularly those with high genomic instability or DNA-repair defects, may have a relatively higher mutational burden and the potential to generate neoantigens. Nevertheless, the immune response is often ineffective because of functional T-cell exhaustion and the presence of regulatory T cells and myeloid-derived suppressor cells.

Integrated analyses have identified several major biological subtypes:

• chromosomally unstable subtype: characterized by extensive structural alterations and receptor amplifications;
• metabolic-inflammatory subtype: associated with a strong inflammatory imprint and metabolic adaptations;
• altered DNA damage response subtype: with defects in repair mechanisms and greater sensitivity to genomic stress.

Although not yet routinely applied, these profiles explain part of the clinical and therapeutic variability.

From a metabolic standpoint, neoplastic cells display marked adaptive flexibility. Aerobic glycolysis coexists with efficient glutamine use and remodeling of lipid metabolism in response to hypoxia and nutrient stress. Antioxidant mechanisms are enhanced to counter the excess reactive oxygen species generated by chronic inflammation. Recent studies suggest possible involvement of alternative regulated cell-death pathways, such as ferroptosis, with therapeutic implications that remain under investigation.

The histological component of esophageal adenocarcinoma shows considerable morphological variability. Well-differentiated tumors contain well-formed glands, sometimes mucin-secreting, with relatively preserved architecture; moderately differentiated tumors show greater disorganization and cytological atypia; poorly differentiated tumors are characterized by solid patterns, a high mitotic index, and marked invasiveness. Histological variants include mucinous, signet-ring cell, and poorly cohesive forms, which are associated with more aggressive behavior.

Immunohistochemistry supports diagnostic and prognostic characterization: CK7, CK20, and CDX2 confirm intestinal-type glandular differentiation, whereas HER2 may be overexpressed in a proportion of cases. Ki-67 provides information on the proliferative fraction. Lymphatic, vascular, and perineural invasion are morphological indicators of biological aggressiveness.

Preclinical models, including organoids derived from esophageal adenocarcinoma and PDX models, have made it possible to reproduce clonal heterogeneity and investigate mechanisms of therapeutic resistance. Single-cell sequencing is clarifying the organization of tumor and stromal populations and identifying subclones with stem-like properties and metastatic potential. Taken together, these data define esophageal adenocarcinoma as a complex neoplasm driven by the interaction of chronic inflammatory injury, multiple molecular alterations, a permissive microenvironment, and metabolic adaptations.

The clinical manifestations of esophageal adenocarcinoma result from the combination of progressive luminal obstruction, infiltration of the esophageal wall, and the systemic effects of disease. In the early stages, particularly when the tumor is confined to the mucosa or submucosa, patients may have few or no symptoms. At this stage, the diagnosis may be made incidentally during esophagogastroduodenoscopy performed for persistent reflux symptoms, unexplained iron-deficiency anemia, or follow-up of known Barrett esophagus. The absence of specific early symptoms contributes to frequent diagnostic delay.

The most common symptom is dysphagia, which generally develops insidiously and progresses over time. It initially affects solid foods, with a sensation that the bolus is slowing or stopping behind the sternum, often accompanied by the need to drink to facilitate swallowing. As luminal stenosis worsens and the wall loses elasticity, dysphagia becomes constant and also affects semisolid foods and liquids. Some patients have odynophagia, reflecting mucosal ulceration or nerve infiltration.

Progressive dysphagia leads to changes in eating habits, reduced caloric intake, and consequent weight loss. Fatigue, reduced exercise tolerance, and signs of malnutrition are often associated. Retrosternal pain may occur, sometimes radiating to the back or epigastric region, and may be misinterpreted as a cardiac or dyspeptic disorder, contributing to delays in specialist assessment. Regurgitation of food, sialorrhea, and a sensation of stasis may occur, especially in advanced stages.

Symptoms vary according to the predominant tumor site:

• adenocarcinomas of the gastroesophageal junction: often associated with heartburn, acid regurgitation, and worsening reflux symptoms;
• distal lesions: progressive dysphagia and epigastric or retrosternal pain;
• proximal lesions, which are less common: early dysphagia and a foreign-body sensation;
• at any site, the triad of worsening dysphagia, weight loss, and pain should raise diagnostic suspicion.

Local progression with invasion of adjacent structures may cause severe complications. Airway involvement leads to persistent cough, dyspnea, and recurrent respiratory infections. The formation of esophagotracheal fistulas presents with violent coughing during eating and frequent episodes of aspiration. Extension to the pleura, pericardium, or mediastinum may cause chest pain, pleural or pericardial effusions, and, in the most severe cases, hemodynamic compromise. Recurrent laryngeal nerve involvement causes hoarseness and dysphonia.

Ulceration of the tumor surface may cause chronic bleeding and iron-deficiency anemia, characterized by pallor, easy fatigability, and tachycardia. Hematemesis or melena is less common but indicates more substantial bleeding. Advanced disease is often accompanied by cancer cachexia, with loss of muscle mass, anorexia, and marked reduction in physical performance.

Regional lymph-node spread may become apparent as supraclavicular or cervical lymphadenopathy. Distant metastases cause organ-specific symptoms, such as bone pain from skeletal lesions, dyspnea from pulmonary metastases, jaundice and abdominal pain from hepatic involvement, or focal neurological signs when the brain is affected. Disseminated disease is often associated with rapid clinical deterioration and worsening general condition.

A minority of patients may develop paraneoplastic syndromes, including thromboembolic manifestations, metabolic abnormalities, and neurological or cutaneous disorders. Physical examination commonly shows signs of malnutrition, anemia, and lymphadenopathy. The typical presentation is that of a middle-aged or older patient, often with a history of chronic gastroesophageal reflux disease and Barrett esophagus, reporting progressive dysphagia, weight loss, and fatigue.

The diagnostic workup for esophageal adenocarcinoma begins with well-founded clinical suspicion and follows a rational sequence of investigations aimed first at histological demonstration of the neoplasm, then at excluding alternative diagnoses, and finally at defining disease extent, before formal staging is introduced. Clinical suspicion typically arises in the presence of progressive dysphagia initially affecting solid foods, unintentional weight loss, worsening heartburn refractory to treatment, acid regurgitation, unexplained iron-deficiency anemia, persistent retrosternal pain, or occult gastrointestinal bleeding. These symptoms are particularly significant in individuals with known risk factors such as chronic gastroesophageal reflux disease, longstanding Barrett esophagus, visceral obesity, male sex, older age, and smoking. In this setting, the first clinical objective is to recognize a suggestive presentation promptly and refer the patient for timely endoscopic assessment, avoiding prolonged or low-yield diagnostic pathways.

The cornerstone of diagnosis is esophagogastroduodenoscopy, which is the first truly decisive specialist examination. In accordance with major international guidelines, EGD is the first-line investigation and does not routinely require a preliminary contrast radiographic study, except in selected situations such as extremely tight stenosis or conditions that make the safety of endoscopy uncertain. Endoscopy should be performed with high-definition equipment and accompanied by a systematic description of the lesion, including its exact location relative to the incisors, longitudinal extent, relationship to the gastroesophageal junction, macroscopic appearance (exophytic, ulcerated, infiltrative, stenosing, or flat), degree of luminal compromise, and whether the endoscope can traverse it. Complete inspection of the esophagus and cardia is essential to identify any synchronous lesions and assess the mucosal background, particularly the presence of Barrett epithelium.

In esophageal adenocarcinoma, advanced endoscopic imaging techniques are particularly important in early disease and in the setting of Barrett esophagus. Methods such as NBI, BLI, or FICE improve characterization of the mucosal surface and vascular pattern, facilitating identification of dysplastic or neoplastic areas that may not be immediately apparent under white light alone. Optical magnification allows assessment of architectural and vascular irregularities suggestive of neoplastic transformation, contributing to more accurate delineation of lesion margins and detection of multifocal foci.

During endoscopy, multiple biopsies are obtained and are central to definitive diagnosis. Numerous representative samples should be taken from different areas of the lesion, including central and peripheral portions, to reduce the risk of false-negative results related to superficial necrosis or histological heterogeneity. If a tight stenosis prevents passage of a standard endoscope, smaller-caliber instruments may be used to reach the critical segment and obtain adequate specimens. When repeated biopsies are nondiagnostic despite a highly suspicious endoscopic appearance, macrobiopsies or diagnostic endoscopic procedures such as endoscopic mucosal resection or submucosal dissection may be considered, particularly for superficial lesions, in order to obtain a larger and more informative specimen.

Histopathological examination of the specimens provides the definitive diagnosis of adenocarcinoma. Hematoxylin and eosin staining typically shows atypical glandular structures, architectural disorganization, nuclear pleomorphism, increased mitotic activity, and stromal infiltration. The pathologist determines the degree of differentiation, assesses the presence of mucin, necrosis, vascular or perineural invasion, and, in morphologically ambiguous cases, uses immunohistochemistry to distinguish esophageal adenocarcinoma from other neoplasms, including squamous cell carcinoma, neuroendocrine neoplasms, or metastases of gastric or extragastrointestinal origin. Integration with the clinical context and lesion site is essential for correct attribution of the primary origin, especially in gastroesophageal junction tumors.

According to major international guidelines, a minimum set of clinical and pathological information must be available before a diagnosis of esophageal adenocarcinoma can be considered established and clinical decisions made. These elements are not formal “diagnostic criteria,” but constitute the essential requirements for a reliable diagnosis:

Elements required to establish a diagnosis of esophageal adenocarcinoma

• Endoscopic documentation of a macroscopically suspicious esophageal or gastroesophageal junction lesion in a patient with a compatible clinical presentation.
• Multiple representative biopsies, repeated or supplemented by mucosal resection when initial samples are inconclusive.
• Histological demonstration of adenocarcinoma with typical glandular features.
• Use of immunohistochemistry in poorly differentiated cases or when the differential diagnosis is complex.
• Exclusion, based on the clinical context and complementary investigations, of metastatic adenocarcinoma from another primary site.

Once histological confirmation has been obtained, the differential diagnosis must be addressed systematically. Among neoplastic conditions, esophageal adenocarcinoma must be distinguished from squamous cell carcinoma and proximal gastric adenocarcinoma, particularly for tumors of the gastroesophageal junction, by integrating site, extent, and histological characteristics. Neuroendocrine neoplasms, gastrointestinal stromal tumors, lymphomas, and esophageal metastases from other solid tumors must also be considered. Among non-neoplastic conditions, stenosis and ulceration may be related to severe reflux esophagitis, cicatricial changes, complicated peptic ulcers, or motility disorders; in these cases, endoscopy with targeted biopsies and functional testing allow correct diagnostic definition. Extrinsic compression from mediastinal masses or adjacent structures should be considered when endoscopy shows intact mucosa with deformation of the lumen.

After the diagnosis has been confirmed, subsequent investigations are directed toward assessment of disease extent. Endoscopic ultrasound allows precise analysis of the layers of the esophageal wall and periesophageal tissues, estimating the depth of invasion and identifying suspicious regional lymph nodes. When lymph nodes have suggestive ultrasonographic features, endoscopic ultrasound-guided fine-needle aspiration provides cytological material to confirm neoplastic involvement. Contrast-enhanced computed tomography of the chest and abdomen is essential for locoregional assessment and the search for distant metastases. 18F-FDG PET provides additional functional information useful for identifying metastatic foci not apparent on CT alone and for better characterization of suspicious lymph nodes. In selected cases, further investigations such as bronchoscopy or otolaryngological assessment may be indicated according to the site and symptoms.

In summary, the diagnostic assessment of esophageal adenocarcinoma follows a practical and progressive sequence: recognition of clinical suspicion; esophagogastroduodenoscopy with advanced imaging and multiple biopsies; histological confirmation with immunohistochemical support when needed; definition of the differential diagnosis; and then assessment of disease extent by endoscopic ultrasound, computed tomography, PET, and targeted investigations based on the site and clinical presentation.

The staging of esophageal adenocarcinoma integrates clinical, endoscopic, and radiological data obtained during the diagnostic workup and makes it possible to describe the anatomical extent of disease in a standardized manner, distinguish early disease from locally advanced or metastatic forms, and provide prognostic guidance. The international reference is the eighth edition of the AJCC/UICC TNM system, which includes clinical staging, pathological staging after primary surgery, and pathological staging after preoperative treatment. For adenocarcinoma, the TNM system uses stage groupings distinct from those for squamous cell carcinoma, reflecting biological and prognostic differences.

Clinical staging is based on integrating endoscopic ultrasound findings, which are fundamental for assessing depth of infiltration and regional lymph-node status, with contrast-enhanced computed tomography of the chest and abdomen to evaluate locoregional extension and search for distant metastases. 18F-FDG PET contributes to the identification of metabolically active foci not apparent on CT alone and improves characterization of suspicious lymph nodes. The information collected is assigned to T, N, and M categories and then to clinical stage groups, which provide a practical summary of disease extent.

From a prognostic standpoint, the main determinants remain depth of infiltration of the esophageal wall, number of metastatic lymph nodes, and presence of distant metastases. The TNM system describes anatomical progression from superficial lesions limited to the mucosa to forms with systemic spread. Prognosis is generally favorable for early tumors confined to the mucosa or submucosa, whereas lymph-node involvement and metastatic disease are associated with a marked deterioration in outcome.

Conceptually, the main stage groups of esophageal adenocarcinoma can be summarized as follows:

Main stage groups in esophageal adenocarcinoma (general concept, AJCC/UICC 8th edition)

• Stage 0: carcinoma in situ or intraepithelial neoplasia confined to the epithelium.
• Stage I: invasive tumor limited to the mucosa or submucosa without lymph-node or distant metastases.
• Stage II: disease with deeper wall infiltration or limited lymph-node involvement.
• Stage III: locally advanced tumor with extensive lymph-node involvement but no distant metastases.
• Stage IV: presence of distant metastases, irrespective of T and N categories.

When a surgical specimen is available without preoperative treatment, pathological staging provides a more accurate prognostic assessment through direct analysis of depth of infiltration, number of lymph nodes examined and involved, margin status, and presence of vascular or perineural invasion. In patients who have received preoperative therapy, ypTNM staging describes the amount of residual disease and distinguishes complete pathological responses from cases with substantial persistent tumor, with important prognostic implications.

Survival curves show a clear correlation between stage and outcome. In cohorts treated with a multimodal approach, 5-year survival varies widely according to stage, being high in early disease and markedly lower in advanced and metastatic forms. Population-based analyses show lower overall survival than selected surgical series, reflecting the frequent diagnosis at an advanced stage. Achieving complete resection and diagnosing disease while still localized remain the principal factors associated with a favorable prognosis.

In addition to anatomical stage, several additional prognostic factors influence outcome. Important tumor-related factors include histological grade, longitudinal extent of the lesion, number and ratio of metastatic lymph nodes, and the presence of vascular or perineural invasion. In patients receiving radiotherapy, the tumor volume used in treatment planning is associated with local control and survival. Patient-related factors, including performance status, nutritional status, weight loss, and comorbidities, significantly affect prognosis and treatment tolerability.

In recent years, numerous molecular biomarkers with potential prognostic value have been evaluated, including immune-interaction parameters such as PD-L1 expression. None, however, has replaced TNM staging in routine clinical practice, and the most widely used approach remains integration of anatomical staging with clinical, nutritional, and functional factors.

Overall, staging of esophageal adenocarcinoma is an integrated process combining anatomical extent, histological characteristics, and the patient’s general condition. Early-stage disease may achieve high long-term survival, whereas in advanced stages prognosis is strongly affected by lymph-node burden and the presence of metastases. In metastatic disease, the primary objective remains symptom control and preservation of quality of life.

Treatment of esophageal adenocarcinoma is based on a multimodal and individualized approach integrating therapeutic endoscopy, surgery, radiotherapy, chemotherapy, and immunotherapy in a sequence determined by disease extent, tumor site, biological characteristics, functional status, and comorbidities. Therapeutic decisions should be made within an experienced multidisciplinary team, because management of esophageal adenocarcinoma spans a continuum from curative endoscopic treatment of early disease to palliative systemic therapy for advanced stages, always accompanied by appropriate nutritional and symptomatic support.

In very early forms limited to the mucosa (Tis or T1a), without submucosal infiltration, lymphovascular invasion, or other high-risk histological factors, endoscopic resection is an established curative strategy. Endoscopic mucosal resection is indicated for small lesions, whereas endoscopic submucosal dissection (ESD) enables en bloc resection of larger neoplasms and accurate assessment of margins and depth of invasion. Patient selection requires rigorous staging to exclude lymph-node involvement. With histologically negative margins and disease confined to the mucosa, resection may be considered definitive and followed by a structured endoscopic surveillance program. Conversely, documentation of submucosal invasion, positive or close margins, lymphovascular invasion, or perineural invasion requires therapeutic reassessment, generally leading to surgery with lymphadenectomy or, in inoperable patients, nonsurgical strategies. In frail individuals or those at high operative risk, a less invasive approach may be adopted after careful individualized assessment of the risk–benefit balance.

For locally advanced but resectable disease, Western guidelines recommend neoadjuvant chemoradiotherapy followed by surgery as the standard approach. The most commonly used regimens combine a platinum compound and fluoropyrimidine or carboplatin and paclitaxel with radiotherapy, generally at doses between 41.4 and 50.4 Gy. This approach aims to reduce tumor volume, increase the likelihood of complete (R0) resection, and treat occult micrometastases. Post-neoadjuvant reassessment by imaging and clinical evaluation confirms surgical candidacy and excludes systemic progression, allowing the therapeutic strategy to be adjusted according to response.

In some settings, particularly in selected patients with adenocarcinoma of the gastroesophageal junction, perioperative chemotherapy without radiotherapy is used, with modern fluoropyrimidine-, platinum-, and taxane-based regimens. This strategy, established in European practice, provides early systemic treatment and continuation of therapy after surgery when adequately tolerated. The choice between neoadjuvant chemoradiotherapy and perioperative chemotherapy depends on the site, stage, biological profile, institutional expertise, and the patient’s clinical characteristics.

Surgery is central to the treatment of resectable disease. The objective is an R0 resection together with oncologically adequate lymphadenectomy. The reference procedure is esophagectomy with reconstruction of gastrointestinal continuity, most commonly using a gastric conduit; when the stomach is unsuitable, colonic interposition or, in selected cases, a microvascular jejunal graft may be used. The extent of lymph-node dissection is determined by tumor site, with standardized approaches for distal and junctional tumors.

The main surgical techniques include transthoracic and transhiatal approaches. The Ivor Lewis procedure, with an intrathoracic anastomosis, is frequently used for distal and junctional tumors, whereas the McKeown technique uses a cervical anastomosis and is selected in specific settings to limit the clinical consequences of any anastomotic leak. The transhiatal approach avoids thoracotomy but may reduce the extent of mediastinal clearance. Minimally invasive and robotic approaches have become increasingly common and are associated with less surgical trauma and faster functional recovery when performed in high-volume centers. Determinants of outcome include margin quality, adequacy of lymphadenectomy, perfusion of the gastric conduit, and the anastomotic technique used.

In patients treated with neoadjuvant chemoradiotherapy and surgery who have residual pathological disease, adjuvant immunotherapy may be indicated. Randomized clinical trials have shown that prolonged administration of a PD-1 inhibitor after esophagectomy improves recurrence-free survival compared with observation alone. Candidate selection takes into account residual pathological stage, response to preoperative therapy, and the individual risk profile, with careful assessment of autoimmune disease and potential immune-mediated toxicity.

For patients with unresectable locally advanced disease or those who are not surgical candidates because of comorbidities, limited functional reserve, or informed refusal, definitive chemoradiotherapy is a potentially curative option. The most widely used protocols combine cisplatin and a fluoropyrimidine or carboplatin and paclitaxel with radiotherapy at total doses generally between 50 and 60 Gy, adapting volumes and fractionation to the tumor site and extent. In cases of persistent or locally recurrent disease, salvage surgery may be considered in carefully selected patients, although it carries an increased risk of complications; in other settings, endoscopic or palliative local-control strategies are used.

In recurrent or metastatic disease, treatment is mainly palliative and aims to prolong survival and preserve quality of life. First-line regimens include platinum and fluoropyrimidine combinations, often integrated with anti-PD-1 immunotherapy. Late-phase studies have demonstrated a survival benefit with combinations including nivolumab or pembrolizumab, with a greater effect in subgroups with higher PD-L1 expression. Taxanes, irinotecan, and other cytotoxic agents remain available in subsequent lines, with selection guided by previous response, tolerability, and the patient’s clinical condition.

Management of mechanical complications, particularly dysphagia, is an integral part of treatment. Placement of self-expanding esophageal stents rapidly improves food transit, either as a bridge to curative-intent treatment or for palliation. Alternatively or in combination, palliative radiotherapy or endoluminal brachytherapy may reduce obstruction and improve swallowing. Selected endoscopic procedures, such as dilation or hemostatic treatment, should be considered in light of perforation risk, expected duration of benefit, and overall prognosis.

Nutritional support and toxicity management are cross-cutting components of the entire therapeutic pathway. Protein-calorie malnutrition and sarcopenia are common and adversely affect treatment tolerance and outcome. Early involvement of dietitians and dedicated teams enables individualized interventions including dietary modification, oral supplementation, and enteral or parenteral nutrition. At the same time, hematological, gastrointestinal, neurological, and immune-mediated toxicities require active monitoring and prompt management. Control of pain, dysphagia, and psychological burden should be integrated from the outset, with early involvement of palliative care for patients with complex symptoms or an unfavorable prognosis.

Follow-up and post-treatment surveillance of esophageal adenocarcinoma are essential components of care, aimed at detecting local or distant recurrence early, identifying any second primary tumors, monitoring late treatment complications, and ensuring adequate nutritional and functional support. Follow-up is tailored to the initial stage, type of treatment received, and response achieved, and requires dynamic multidisciplinary planning.

In patients who have undergone curative endoscopic resection for superficial adenocarcinoma confined to the mucosa, surveillance is predominantly endoscopic. Examinations aim to identify local recurrence and new dysplastic or neoplastic lesions in an esophagus often affected by Barrett metaplasia. Endoscopies are scheduled more frequently during the first few years and use targeted biopsies and advanced imaging techniques. In the absence of suspicious findings, systematic radiological follow-up is generally not indicated.

After curative-intent esophagectomy, with or without preoperative therapy, follow-up is multidimensional. During the first two or three years, when the risk of recurrence is highest, clinical assessments are generally performed every 3–6 months and include symptom evaluation, physical examination, nutritional monitoring, and review of comorbidities. Contrast-enhanced CT of the chest and abdomen is used at regular intervals for oncological surveillance, whereas endoscopy is reserved for patients with suggestive symptoms or radiological findings requiring clarification.

In patients treated with definitive chemoradiotherapy, follow-up requires particular attention because distinguishing complete response from residual disease and recurrence can be difficult. Initial response assessment is performed with CT and, in selected cases, 18F-FDG PET, while considering the possibility of nonspecific post-radiation uptake. Endoscopy with targeted biopsies retains a central role in local assessment, particularly in the presence of persistent mucosal abnormalities or symptoms.

An important aspect of follow-up is surveillance for second primary tumors of the upper aerodigestive tract, particularly in patients with persistent risk factors. Clinical assessment of the head and neck region should be systematic, with targeted endoscopic investigations when suspicious signs or symptoms are present.

Follow-up also includes management of functional and nutritional sequelae. After esophagectomy, functional dysphagia, reflux, dumping syndrome, early satiety, and chronic weight loss are common. Nutritional and functional monitoring is essential to prevent malnutrition and sarcopenia. Patients who have received chemoradiotherapy should also be monitored for late toxicities, including esophageal stenosis, mediastinal fibrosis, radiation pneumonitis, and cardiac complications.

The overall duration of follow-up is generally at least five years, with greater intensity during the first two or three years and progressively longer intervals in disease-free patients. In later phases, attention focuses increasingly on management of comorbidities and functional sequelae and on prevention of new clinically significant events. At every stage, follow-up should remain flexible and individualized, integrating oncological surveillance with quality-of-life assessment.

In summary, follow-up of esophageal adenocarcinoma requires a structured, multidimensional approach combining oncological surveillance, management of late complications, and nutritional and functional support, with the aim of preserving the best possible long-term level of autonomy and quality of life.

Long-term quality-of-life considerations in esophageal adenocarcinoma are an essential dimension of care and are becoming increasingly important as therapeutic outcomes and survival improve. Even after oncological control has been achieved, many patients experience persistent consequences of the disease and its treatments that substantially affect daily life. Quality-of-life assessment should therefore be permanently integrated into follow-up as an indispensable component of comprehensive care.

A central area is swallowing function. After esophagectomy with gastroesophageal reconstruction, the physiology of food transit is profoundly altered, and mild to moderate dysphagia for solids, early satiety, and the need to adapt meal consistency and eating patterns over time are common. In patients who have received chemoradiotherapy, fibrosis and cicatricial stenosis may cause chronic swallowing difficulties. Structured functional monitoring and swallowing-rehabilitation programs promote better long-term adaptation.

Gastroesophageal and bile reflux is particularly common after surgery, especially in the absence of an effective antireflux mechanism. Regurgitation, atypical heartburn, nocturnal cough, and sleep disturbances may persist and require management based on dietary modifications, appropriate posture, and lasting lifestyle changes supported by continuous clinical care.

Postprandial metabolic disturbances, including the various forms of dumping syndrome, substantially affect personal autonomy and social life. Symptoms such as tachycardia, sweating, abdominal pain, diarrhea, or late hypoglycemia require major reorganization of eating habits, with divided meals and targeted nutrient distribution, making long-term nutritional follow-up essential.

Nutrition and body composition directly influence quality of life. Persistent weight loss, loss of muscle mass, and malnutrition are common and are associated with greater frailty, reduced exercise tolerance, and impaired functional independence. Periodic monitoring of weight, lean mass, and caloric intake, together with individualized nutritional interventions, is fundamental to preserving overall well-being.

Treatment sequelae may also involve respiratory and vocal function. Chronic cough, reduced respiratory capacity, persistent hoarseness, or vocal fatigue interfere with communication, employment, and social relationships. A multidisciplinary rehabilitation approach can reduce the impact of these disorders and improve functional recovery over time.

The psychological and psychosocial dimension is crucial. The often complex and prolonged diagnostic and therapeutic pathway for esophageal adenocarcinoma may cause lasting emotional consequences, such as anxiety, depressive symptoms, fear of recurrence, and altered body image. Dietary and functional limitations may reduce social participation and adversely affect interpersonal relationships. Structured psychological support and continuous communication with the care team promote better adaptation to long-term survivorship.

Overall, long-term quality of life depends on the healthcare system’s ability to provide integrated care that combines oncological surveillance with management of functional, nutritional, and psychological sequelae. In this context, quality of life is a priority clinical outcome and should be considered alongside traditional efficacy indicators when evaluating the overall success of treatment for esophageal adenocarcinoma.

Complications of esophageal adenocarcinoma arise from the interaction between disease progression, therapeutic strategies, and invasive procedures, creating a complex clinical picture that requires continuous surveillance and multidisciplinary management. In the early stages, progressive obstruction of the esophageal lumen may cause worsening dysphagia, reduced caloric intake, and malnutrition, whereas the consequences of locoregional extension and systemic impairment predominate in advanced disease. Early assessment of nutritional and functional status is critical because frailty and loss of lean mass increase the risk of infection and treatment-related toxicity.

Local tumor progression is associated with a continuous worsening of dysphagia, potentially leading to complete inability to eat, with an increased risk of aspiration and aspiration pneumonia, particularly when swallowing dysfunction is present. Invasion of adjacent structures may cause persistent retrosternal pain, chronic cough, dysphonia, and dyspnea. The development of esophagorespiratory fistulas is a particularly serious complication associated with recurrent pulmonary infections and an unfavorable prognosis. In more advanced cases, erosion of major mediastinal vessels may cause rapidly fatal hemorrhage, while cachexia, venous thromboembolism, and paraneoplastic syndromes contribute to overall clinical deterioration.

Esophageal surgery carries a significant risk of complications. Respiratory complications, particularly pneumonia, are among the leading causes of postoperative morbidity. Anastomotic leakage is a feared event and may occur early because of vascular-supply problems or later in association with local infection. Late anastomotic strictures may require repeated endoscopic dilations, with a cumulative risk of perforation. Chylothorax, resulting from thoracic duct injury during lymphadenectomy, causes substantial fluid and protein loss. Postoperative arrhythmias and recurrent laryngeal nerve injuries complete the spectrum of major surgical complications.

Chemoradiotherapy is associated with acute and late toxicities. Common manifestations include esophagitis and mucositis, which cause severe pain, marked dysphagia, and further deterioration of nutritional status. Cytopenias increase infectious and bleeding risks, whereas radiotherapy may induce radiation pneumonitis, mediastinal fibrosis, and pericarditis. Chronic esophageal stenosis may develop over time and, more rarely, esophagorespiratory or esophagoaortic fistulas, often with rapidly fatal progression. Cardiopulmonary involvement is more likely in the presence of comorbidities or high-dose treatment.

Immunotherapy may cause immune-mediated adverse events affecting several organs. The most clinically significant complications include immune-mediated pneumonitis, colitis, hepatitis, thyroid and adrenal endocrinopathies, skin manifestations, and nephritis. Although uncommon, conditions such as immune-mediated myocarditis are associated with high mortality and require prompt recognition and treatment. Management of these toxicities requires close clinical and laboratory monitoring.

Endoscopic procedures used to treat dysphagia or superficial lesions carry specific risks. Self-expanding stents may cause pain, migration, ulceration, perforation, or fistulas, particularly in esophagi already compromised by post-radiation fibrosis. Endoscopic dilation carries a risk of perforation that is higher in tight, rigid stenoses. Resection or ablation techniques may be complicated by bleeding, perforation, and late cicatricial stenosis.

Systemically, cancer cachexia, opportunistic infections, and thromboembolic events are important determinants of poor prognosis. Progressive functional decline requires a comprehensive approach that integrates symptom control, nutritional support, and, when appropriate, palliative care at an early stage.

Effective complication management is based on structured prevention, including early nutritional screening, optimization of respiratory function, pain control, physiotherapy, management of comorbidities, and prompt recognition of signs of toxicity or infection. Multidisciplinary integration reduces the severity of adverse events, improves quality of life, and enables as many patients as possible to complete treatment pathways in the best possible clinical condition.